Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 36 of 116

  1. BNT327, BNT323

    BioNTech SE

    Advanced Breast Cancer Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  2. BNT327, BNT324

    BioNTech SE

    Advanced Lung Cancer

    phase 2 small molecule active

    1 trial

  3. BNT327, DOCETAXEL

    BioNTech SE

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  4. BNT329

    BioNTech SE

    Advanced Solid Cancers

    phase 2 small molecule active

    1 trial

  5. BO25430

    Hoffmann-La Roche

    Metastatic Cancer

    phase 2 small molecule active

    1 trial

  6. BO39610

    Hoffmann-La Roche

    Metastatic non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  7. BO41932

    Hoffmann-La Roche

    Solid tumors

    phase 2 small molecule active

    1 trial

  8. BO42533

    Hoffmann-La Roche

    Squamous cell carcinoma of the head and neck (SCCHN)

    phase 2 small molecule active

    1 trial

  9. BO43249

    Hoffmann-La Roche

    Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  10. BO43936

    Hoffmann-La Roche

    Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

    phase 2 other active

    1 trial

  11. BO44157

    Hoffmann-La Roche

    Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  12. BO44178

    Hoffmann-La Roche

    Previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)

    phase 2 other active

    1 trial

  13. BO44426

    Hoffmann-La Roche

    Untreated Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  14. BO45853

    Hoffmann-La Roche

    Early-Stage, PIK3CA-Mutated Breast Cancer (BC)

    phase 2 small molecule active

    1 trial

  15. BP41072

    Hoffmann-La Roche

    Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)

    phase 2 small molecule active

    1 trial

  16. BP42772

    Hoffmann-La Roche

    Advanced or metastatic squamous cell carcinoma of the esophagus

    phase 2 other active

    1 trial

  17. BP45381

    Hoffmann-La Roche

    BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)

    phase 2 small molecule active

    1 trial

  18. BPF-CCRT (run-in)

    Hospital Authority, Hong Kong

    Stage III Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  19. BSMO 1-2018

    Wuhan Createrna Science and Technology Co., Ltd

    Basket tumors

    phase 2 small molecule active

    1 trial

  20. BT8009, Zelenectide Pevedotin

    BICYCLE THERAPEUTICS

    NECTIN4 Amplified Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  21. BXCL701

    BioXcel Therapeutics

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  22. BXCL701 plus Pembrolizumab

    BioXcel Therapeutics

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  23. Bactrim + compresse for Chronic Lymphocytic Leukemia

    Fondazione Telethon ETS

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  24. Balugrastim

    Teva Pharma GmbH

    Solid Tumors

    phase 2 small molecule terminated

    1 trial

  25. Bavencio 20 mg/mL concentrate for solution for infusion

    Disc Medicine

    locally advanced urothelial cancer.

    phase 2 small molecule active

    1 trial

  26. Becotatug Vedotin

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma (NPC)

    phase 2 small molecule active

    1 trial

  27. Becotatug Vedotin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  28. Becotatug Vedotin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Penile Cancer

    phase 2 small molecule active

    1 trial

  29. Belzutifan

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Renal Cell

    phase 2 small molecule active

    1 trial

  30. Bemarituzumab

    Prime Medicine

    Gastric Cancer

    phase 2 mab completed

    1 trial

  31. Bemarituzumab + Flot regimen

    United Therapeutics Europe Ltd

    Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas

    phase 2 small molecule terminated

    1 trial

  32. Bempegaldesleukin

    Nektar Therapeutics UK Limited

    Urinary Bladder Neoplasm

    phase 2 mab completed

    1 trial

  33. Bendamustine

    Teva Pharma GmbH

    Mantle Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  34. Bendamustine

    Teva Pharma GmbH

    Leukemia

    phase 2 small molecule completed

    1 trial

  35. Bendamustine

    Adaptive Biotechnologies Corp

    Lymphoma

    phase 2 small molecule active

    1 trial

  36. Bendamustine hydrochloride

    Teva Pharma GmbH

    Non-Hodgkin's Lymphoma (NHL)

    phase 2 small molecule completed

    1 trial

  37. Benmelstobart

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  38. Berubicin hydrochloride

    Rani Therapeutics Holdings

    central nervous system (CNS) lymphomas

    phase 2 small molecule active

    1 trial

  39. Bevacizumab

    United Therapeutics Europe Ltd

    Colorectal Adenocarcinoma

    phase 2 mab completed

    1 trial

  40. Bevacizumab

    United Therapeutics Europe Ltd

    Metastatic Melanoma

    phase 2 mab completed

    1 trial

  41. Bevacizumab

    The First People's Hospital of Lianyungang

    Lung, Carcinoma

    phase 2 small molecule active

    1 trial

  42. Bevacizumab

    The First People's Hospital of Lianyungang

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  43. Bevacizumab

    BRIGHT MINDS BIOSCIENCES INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  44. Bevacizumab

    BRIGHT MINDS BIOSCIENCES INC.

    Colorectal Neoplasms

    phase 2 small molecule terminated

    1 trial

  45. Bevacizumab

    ONCOLYTICS BIOTECH INC

    Ras-mutated Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  46. Bevacizumab combined with Oxaliplatin and TAS-102

    The First People's Hospital of Lianyungang

    Advanced Colorectal Cancer

    phase 2 small molecule active

    1 trial

  47. Bexarotene

    LIGAND PHARMACEUTICALS INC

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  48. Bexarotene

    LIGAND PHARMACEUTICALS INC

    Sarcoma, Kaposi

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.